Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

92P - Analysis of standard serum biomarker levels in patients with non-specific symptoms seen at Guy´s rapid diagnostic clinic


10 Sep 2022


Poster session 01


Laboratory Diagnostics;  Translational Research;  Cancer Epidemiology

Tumour Site


Maria Monroy Iglesias


Annals of Oncology (2022) 33 (suppl_7): S27-S54. 10.1016/annonc/annonc1037


M.J. Monroy Iglesias

Author affiliations

  • Translational Oncology And Urology Research, KCL - King's College London, WC2R 2LS - London/GB

Abstract 92P


Rapid diagnostic clinics (RDCs) were set up by NHS England to provide an alternative pathway for patients with non-specific symptoms (e.g. weight loss and fatigue) concerning of malignancy, who are not suitable for a site-specific route. The aim of the current study was to perform a preliminary analysis of the serum biomarker levels of patients attending an RDC and subsequently diagnosed with cancer, as compared to those patients diagnosed with a mild benign disease or with no clear organic cause for their symptoms.


We analyzed the current panel of standard serum biomarkers taken at referral for patients seen at Guy´s RDC between December 2016 and April 2022. We compared the distribution of biomarkers based on the clinical cut-off levels between those diagnosed with cancer (n=283) and those with a mild benign diagnosis or with unknown cause for their symptoms (n=1,787).


The biggest differences were observed for inflammatory markers (i.e., erythrocyte sedimentation rate (ESR), ferritin, lactate dehydrogenase (LDH), C reactive protein (CRP)), albumin, alkaline phosphatase (ALP), and serum free light chain (SFLC) ratio. Compared with the non-cancer population, more cancer patients had high levels of ESR (³14mm/hr) (36% (n=103) vs 17% (n=301)), ferritin (³276ug/L) (21% (n=59) vs 6% (n=108)), LDH (³225 U/L) (34% (n=95) vs 17% (n=302)), CRP (³4 mg/L) (56% (n=157) vs 20% (n=356)), ALP (³130mL/min) (27% (n=77) vs 5% (n=86)), platelets (³400x109) (11% (n=31) vs 3% (n=45)), and SFLC ratio (³1.65) (12% (n=33) vs 4% (n=68)). Conversely, 25% (n=70) of cancer patients had low albumin levels (<40 g/L) compared with 4% (n=68) of the non-cancer population.


Preliminary descriptive analysis of data showed that cancer patients with non-specific symptoms commonly present with abnormal inflammatory markers, albumin, ALP, platelets, and SFLC ratio, compared with patients diagnosed with a mild benign disease or with no clear organic cause for their symptoms. This is the first step in the development of a risk-stratification tool which will aid in the early diagnosis of cancer in patients who present with non-specific symptoms in the RDC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.


Has not received any funding.


The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.